NEW YORK, Feb. 16, 2021 /PRNewswire/ -- OTC
Markets Group Inc. (OTCQX: OTCM), operator of financial
markets for 11,000 U.S. and global securities, today announced
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical
stage company leveraging its unique hydrogen sulfide platform to
develop safer medicines for pain and inflammation, has qualified to
trade on the OTCQX® Best Market. Antibe Therapeutics
Inc. upgraded to OTCQX from the OTCQB® Venture
Market.
Antibe Therapeutics Inc. begins trading today on OTCQX under the
symbol "ATBPF." U.S. investors can find current financial
disclosure and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
The OTCQX Market is designed for established, investor-focused
U.S. and international companies. To qualify for OTCQX, companies
must meet high financial standards, follow best practice corporate
governance, and demonstrate compliance with applicable securities
laws. Graduating to the OTCQX Market from the OTCQB Market marks an
important milestone for companies, enabling them to demonstrate
their qualifications and build visibility among U.S. investors.
"We are delighted to upgrade to the OTCQX Best Market," remarked
Scott Curtis, Executive VP of
Antibe. "This initiative advances our capital markets strategy by
emphasizing our commitment to transparency, enhancing liquidity and
expanding access to our stock for U.S. and international
investors."
About Antibe Therapeutics Inc.
Antibe is leveraging
its proprietary hydrogen sulfide platform to develop
next-generation, safer nonsteroidal anti-inflammatory drugs
(NSAIDs) for pain and inflammation arising from a wide range of
medical conditions. Antibe is developing three assets that seek to
overcome the gastrointestinal (GI) ulcers and bleeding associated
with NSAIDs. Antibe's lead drug, otenaproxesul (ATB-346), is
entering Phase III for osteoarthritis pain. Additional assets under
development include a safer alternative to opioids for
peri-operative pain, and a GI-safe alternative to low-dose
aspirin.
About OTC Markets Group Inc.
OTC Markets Group
Inc. (OTCQX: OTCM) operates the OTCQX® Best
Market, the OTCQB® Venture Market and the
Pink® Open Market for 11,000 U.S. and global
securities. Through OTC Link® ATS and OTC Link
ECN, we connect a diverse network of broker-dealers that provide
liquidity and execution services. We enable investors to
easily trade through the broker of their choice and empower
companies to improve the quality of information available for
investors.
To learn more about how we create better informed and more
efficient markets, visit www.otcmarkets.com.
OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated
by OTC Link LLC, member FINRA/SIPC.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212)
896-4428, media@otcmarkets.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-antibe-therapeutics-inc-to-otcqx-301227994.html
SOURCE OTC Markets Group Inc.